Low volume, Gleason 3 + 4 = 7 disease: is active surveillance a realistic option?

It would be easy to misinterpret (or at least “over-interpret”) a recent paper from the group at Johns Hopkins about the pathological outcomes of men initially diagnosed with very low-, low-, or “favorable” intermediate-risk localized disease and treated by immediate radical prostatectomy. … READ MORE …

“Active surveillance: protecting patients from harm”

If you want to get a current update on the management of patients on active surveillance, you need to listed to/watch this presentation by Dr. Lawrence Klotz on the UroToday web site. But you will need 45 minutes. … READ MORE …

Does Test X change what physicians actually do and say to their patients?

One of the key ways in which we can (and do) assess the “value” of new types of medical test is by the degree to which they actually change the ways physicians act on the data and make decisions and/or recommendations about patient management. … READ MORE …

Age, active surveillance, and age-related risk for progression

A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …

Prostate cancer detection and associated risk management

Dr. Michael Barry has been a long-time advocate for caution in the appropriate use of PSA testing and for awareness of the risks of over-treatment of low-risk forms of prostate cancer. … READ MORE …

Howard Wolinsky’s continuing journey on active surveillance

Following his most recent check-in with his urologist, Howard tells us about things related to how the new USPSTF guidelines and tests like liquid biopsies might affect the monitoring of low-risk prostate cancer patients. … READ MORE …

“Active surveillance … how to do it right”

Many readers, and particularly many support group leaders and other educators, may want to read and retain a copy of this very recent article in Oncology. … READ MORE …